Cancer Immunotherapy (Chimeric Antigen Receptor T Cells)

 Cancer Immunotherapy

Cancer immunotherapy with Chimeric Antigen Receptor (CAR) T cells in recent years has been developed rapidly, especially for more aggressive cancers. 

Cancer is one of the leading causes of death worldwide and its prevalence is predicted to continue to increase in the next few years, so increasingly effective therapies are needed.

Research on cancer to date continues to be developed rapidly, especially in terms of therapy. New therapeutic modalities, such as targeted therapy to immunotherapy also continue to be developed and show promising results. 

About 2/3 of all cancer patients are expected to recover with a combination of existing therapies. However, the failure of therapy is also still widely found, especially in cancers that are more aggressive. 

Chimeric Antigen Receptor (CAR) T cells are one of the immunotherapy methods that are being widely developed today. This therapy is considered effective enough to kill cancer cells and has shown promising results, especially for hematological malignancies and some solid tumors.


Edward A. Emmett. Asbestos in High-Risk Communities: Public Health Implications. 2021.

G. I. Walters, A. S. Robertson, P. S. Bhomra, and P. S. Burge. Asbestos is common in a variety of construction industry trades. 2018.

Christopher D Jackson. Asbestosis. 2020.

Berlangganan update artikel terbaru via email:

0 Response to " Cancer Immunotherapy (Chimeric Antigen Receptor T Cells)"

Post a Comment

Iklan Atas Artikel

Iklan Tengah Artikel 1

Iklan Tengah Artikel 2

Iklan Bawah Artikel